Celon Pharma (WAR:CLN) Total Liabilities : zł102.9 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Celon Pharma Total Liabilities?

Celon Pharma's Total Liabilities for the quarter that ended in Sep. 2024 was zł102.9 Mil.

Celon Pharma's quarterly Total Liabilities declined from Mar. 2024 (zł123.18 Mil) to Jun. 2024 (zł116.96 Mil) and declined from Jun. 2024 (zł116.96 Mil) to Sep. 2024 (zł102.91 Mil).

Celon Pharma's annual Total Liabilities increased from Dec. 2021 (zł128.35 Mil) to Dec. 2022 (zł163.12 Mil) but then declined from Dec. 2022 (zł163.12 Mil) to Dec. 2023 (zł123.75 Mil).

Celon Pharma Total Liabilities Historical Data

The historical data trend for Celon Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma Total Liabilities Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

146.31

187.35

128.35

163.12

123.75

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															114.88	123.75	123.18	116.96	102.91

Celon Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Celon Pharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	86.337	+	(5.71	+	31.705
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	123.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	569.308	-	445.556
	=	123.8

Celon Pharma's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	72.27	+	(7.198	+	23.44
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	102.9

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	619.154	-	516.246
	=	102.9

Celon Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Celon Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (WAR:CLN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

8RP:Germany

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines